Enhanced sensitivity has been observed to potentially enhance survival outcomes in Triple Negative Breast Cancer (TNBC) patients characterized by elevated levels of SLFN12 expression, proposing that the expression levels of SLFN12 be considered to serve as a predictive indicator for assessing the efficacy of radiotherapy and chemotherapy in TNBC. Here, SLFN12 is linked to triple-negative breast carcinoma.